May 9, 2024:

Raymond J. Hohl, MD, PhD, was recently named chair of the Cancer Center Directors Committee for the Big Ten Cancer Research Consortium (Big Ten CRC). In this role, Dr. Hohl will help guide strategic priorities for the Big Ten CRC as the consortium enters its second decade. Dr. Hohl has been a member of the leadership committee since the consortium’s founding in 2013 and succeeds Howard Bailey, MD, director of the University of Wisconsin Carbone Cancer Center, as the committee chair.

Dr. Hohl is director of the Penn State Cancer Institute, professor of medicine and pharmacology at the Penn State College of Medicine, Penn State University, and holds a university professorship in medicine. Dr. Hohl is a medical oncologist, hematologist, and clinical pharmacologist with broad experience as a clinical and translational researcher.

Dr. Hohl commented, “I am honored to have been elected to this role and am grateful to my predecessors for their exemplary work. As the Big Ten Cancer Research Consortium continues in its second decade there is much to be done. I am particularly enthusiastic about the ongoing efforts to expand the consortium from its current 15 members to include the new Big Ten institutions. We will foster an environment for the development and running of innovative investigator-initiated studies that match new with seasoned clinical scientists across our member institutions.”

Dr. Hohl began his career at the University of Iowa College of Medicine in 1991. Over the years, he served in a variety of leadership roles at the University of Iowa, including director of the division of hematology, oncology and blood and marrow transplantation at the Roy J. and Lucille A. Carver College of Medicine; director of the fellowship program, division of hematology, oncology and blood and marrow transplantation; associate director for clinical research and associate director for clinical translational research at the Holden Comprehensive Cancer Center; and associate chair in the department of internal medicine.

Dr. Hohl was named director of Penn State Cancer Institute in 2013.

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to more than 9,800 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org.